STI/HIV testing tool for GPs and other primary care clinicians – updated

NSW STI Programs Unit, August 2017

The STI/HIV Testing Tool for GPs and other primary care clinicians has been updated. The tool shows how to:

• Offer routine STI/HIV testing in different consultations

• Conduct a brief risk assessment (sexual history)

• Conduct routine STI/HIV testing

• Conduct contact tracing

• Access available resources and additional support

Based on the Australian STI Management Guidelines, the tool has been developed by GPs with an interest in sexual health, sexual health and public health specialists. The tool is approved by peak bodies including the Royal Australian College of General Practice and the Australian College of Rural and Remote Medicine.

Rescheduling of ulipristal acetate (EllaOne®) in Australia

SHine SA, October 2016

SHine SA and Family Planning Alliance Australia put in submissions to the TGA for the rescheduling of ulipristal acetate (EllaOne®), a new emergency contraceptive pill in Australia.

The rescheduling is from prescription-only to Schedule 3 (available in pharmacies with a pharmacy consultation). This has now been approved, to take place from February 2017.

This is an important access issue.

EllaOne® emergency contraception has also been added to the SHine SA formulary.

Access TGA information about ulipristal acetate (including links to the public submissions) here 

PEP after Non-Occupational and Occupational Exposure to HIV: Australian Guidelines revised

Our apologies to those who tried to access SASHA while it was down. The technical difficulties have now been resolved.

——————————————————————————————————————–

Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine, August 2016

The Second edition of the Post-Exposure Prophylaxis after Non-Occupational and Occupational Exposure to HIV: Australian National Guidelines is now available.

These guidelines outline the management of individuals who have been exposed (or suspect they have been exposed) to HIV in non-occupational and occupational settings.

There are currently no data from randomised controlled trials of the use of post-exposure prophylaxis (PEP) and evidence for use has been extrapolated from animal data, mother to child transmission, occupational exposure and small prospective studies of PEP regimens in HIV-negative men. Accordingly, assumptions are made about the direction of management.

Every presentation for PEP should be assessed on a case-by-case basis, balancing the potential harms and benefits of treatment.

Recommendations following non-occupational exposure have been updated, and information about PEP in the context of pre-exposure prophylaxis (PrEP), PEP and children, renal disease, and gender identity and history has been added.

  • Download the revised guidelines (PDF) here
  • Updates to the supplementary documents, as well as a navigable website for the guidelines, will soon be available. At present, the 2013 literature review and checklist are still available, linked below:

    PEP Checklist (2013)

    Literature Review (2013)

 

New pilot project to improve hep B outcomes for at-risk patients

Burnet Institute, 28 June, 2016

Improved screening of patients at risk of hepatitis B is the aim of a new pilot project underway in Victoria, with early diagnosis and treatment crucial to reduce the risk of liver cancer.

Cancer Council Victoria and Burnet Institute’s Screening for Hepatitis in At-Risk Populations (SHARP) project will trial four new interventions to help diagnose hepatitis B in GP clinics.

The project is targeting patients from countries where hepatitis B is endemic, including Somalia, Sudan, China and Vietnam.

  • Read more here
  • SHARP project details here